Brief: Renovorx Receives New 510(K) Clearance For Its Renovocath Delivery System Designed For Targeted Treatment Of Solid Tumors
07/09/2021 11:47
Sept 7 (Reuters) - RenovoRx Inc RNXT.O :
* RENOVORX RECEIVES NEW 510(K) CLEARANCE FOR ITS RENOVOCATH®
DELIVERY SYSTEM DESIGNED FOR TARGETED TREATMENT OF SOLID TUMORS
Source text for Eikon: ID:nPn5Ckc2Xa
Further company coverage: RNXT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: Renovorx Advances Tamp Into Borderline Resectable Pancreatic Cancer With First Patient Enrolled In Investigator-Initiated Prism-Tamp Trial
RenovoRx Inc reports results for the quarter ended June 30 - Earnings Summary
Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook
Brief: RenovoRx Q2 Net Income USD -2.911 Million
Brief: Renovorx Achieves Major Milestone With Full Enrollment In Phase Iii Tiger-Pac Trial For Locally Advanced Pancreatic Cancer